Tianjin Medical Insurance Bureau recently issued the notice on temporarily including the combined packaging of nimatovir tablets / ritonavir tablets into the payment scope of medical insurance. Since March 14, 2022, according to the diagnosis and treatment specifications, covid-19 insured patients use the combined packaging of nimatovir tablets / ritonavir tablets into the payment scope of medical insurance temporarily. The highest payment standard is linked with the online price of Tianjin pharmaceutical procurement platform and paid according to class a drugs.
Previously, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and approved the import registration of the combined packaging of nevitavir tablets / ritonavir tablets (i.e. paxlovid) of Pfizer covid-19 virus treatment drug conditionally. The product is an oral small molecule COVID-19 virus therapeutic agent for the treatment of mild to moderate New Coronavirus pneumonia (COVID-19) in adults with severe risk factors, such as elderly, chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease.
